Lymphoma: all 5,624 studies
Page 36 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System LymphomaCompletedNCT02669511Phase 2
- Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT02665650Phase 1
- Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
- HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell LymphomaCompletedNCT02660710Phase 2
- Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)WithdrawnNCT02657447Phase 1
- Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLLStatus unknownNCT02656147Phase 1
- Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnNCT02653989Phase 2
- Memory-enriched CAR-T Cells Immunotherapy for B Cell LymphomaStatus unknownNCT02652910Phase 1/2
- Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
- Improving Patient Education for Lymphoma and Leukemia InpatientsCompletedNCT02642510Not applicable
- A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K InhibitorWithdrawnNCT02640833Phase 1
- Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)TerminatedNCT02640209Early Phase 1
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionActive, not recruitingNCT02632396Phase 1/2
- MESA Versus ESA in the Treatment of Early Stage NK/T-cell LymphomaStatus unknownNCT02631239Phase 3
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)CompletedNCT02631044Phase 1
- Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)CompletedNCT02626884Phase 2
- Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin LymphomaTerminatedNCT02624258Early Phase 1
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS LymphomaStatus unknownNCT02623010Phase 2
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
- Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
- Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)WithdrawnNCT02605694Phase 2
- Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCLCompletedNCT02603445Phase 1
- PET-based Evaluation of Chemotherapy-induced Brain Damage in LymphomaCompletedNCT02601547Not applicable
- Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory LymphomaCompletedNCT02598570Phase 1
- Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell LymphomaWithdrawnNCT02595242Phase 1
- A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)CompletedNCT02594267Phase 1
- Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)CompletedNCT02593045Phase 1
- Brazilian Prospective Hodgkin Lymphoma RegistryStatus unknownNCT02589548
- Viral Load Changes in Lymphoma Patients With HCV Infection After ChemotherapyStatus unknownNCT02588560
- To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's LymphomaStatus unknownNCT02585947Phase 4
- A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell LymphomaCompletedNCT02584920Phase 1/2
- QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or LymphomasWithdrawnNCT02582827Phase 1
- Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's LymphomaCompletedNCT02581878Phase 1
- Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLLCompletedNCT02580552Phase 1
- Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)WithdrawnNCT02578511Phase 1
- A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)TerminatedNCT02576665Phase 1
- Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic MalignanciesCompletedNCT02576496Phase 1
- Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)Status unknownNCT02575638Phase 1
- A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidityCompletedNCT02567851Phase 2
- Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic MalignanciesCompletedNCT02566395Phase 3
- Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeStatus unknownNCT02560441Phase 2
- Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin AmericaCompletedNCT02559583
- Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT02556346Phase 1
- Geriatric Assessments in Elderly Diffuse Large B-cell LymphomaCompletedNCT02555267
- MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1
- Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell LymphomaWithdrawnNCT02548468Phase 1
- CD19-targeting CAR T Cells for B Cell LymphomaWithdrawnNCT02547948Phase 1/2
- Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLLStatus unknownNCT02546739Phase 1
- Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)CompletedNCT02546440Phase 2
- Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma PatientsWithdrawnNCT02545361Phase 1/2
- NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage ChemotherapyStatus unknownNCT02544724Phase 2
- VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)Status unknownNCT02544425Phase 2
- Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular LymphomaCompletedNCT02542514Phase 2
- NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)Status unknownNCT02542124Phase 2
- A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCLStatus unknownNCT02542111Phase 2
- Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaWithdrawnNCT02538926Phase 2
- CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCLStatus unknownNCT02533700Phase 2
- P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma PatiensTerminatedNCT02533323Phase 2
- A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaWithdrawnNCT02532192Phase 1
- High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS LymphomaStatus unknownNCT02531841Phase 3
- CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
- Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary LymphomaStatus unknownNCT02526823Phase 4
- Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor PrognosisActive, not recruitingNCT02520908
- Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT02520895
- Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical StudyStatus unknownNCT02520219Phase 2
- Phase 1, Dose-Escalation Study of IGN002 in NHL SubjectsTerminatedNCT02519270Phase 1
- A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and NivolumabCompletedNCT02518958Phase 1
- Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedNCT02512497Phase 1
- Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid MalignanciesStatus unknownNCT02507479Phase 2
- Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)CompletedNCT02504190
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasActive, not recruitingNCT02503423Phase 1/2
- GOAL: GA101 Plus Pixantrone for Relapsed Aggressive LymphomaCompletedNCT02499003Phase 2
- Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell LymphomasStatus unknownNCT02495415Phase 2
- Study of the Angiogenesis by PET/CT in Patients With LymphomaCompletedNCT02490891Phase 2
- Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell LymphomasTerminatedNCT02488512Phase 2
- Lonquek for Autologous Stem Cell MobilizationStatus unknownNCT02488382Phase 1/2
- Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and AdolescentsCompletedNCT02488369Not applicable
- A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibWithdrawnNCT02487316Phase 4
- FDG-PET/CT Imaging as Early Predictor of DPCompletedNCT02476734
- Multicenter Prospective Registry Study of Diffuse Large B Cell LymphomaStatus unknownNCT02474550
- KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell LymphomaCompletedNCT02471911Phase 1
- ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)Active, not recruitingNCT02471391Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
- A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT02460276Phase 2
- INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
- A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's LymphomaStatus unknownNCT02456207Phase 2
- Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)TerminatedNCT02455297Phase 2
- A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell MalignanciesTerminatedNCT02454270Phase 1
- A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT02453087Phase 1
- Rituximab With or Without Ibrutinib for Patients With Advanced Follicular LymphomaTerminatedNCT02451111Phase 2
- Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCLStatus unknownNCT02445404Phase 2
- Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer DiagnosticsStatus unknownNCT02441972Phase 1
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT02436707Phase 2
- ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's LymphomaStatus unknownNCT02431403Phase 1/2
- Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell LymphomaCompletedNCT02424045Phase 2
- Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular LymphomaStatus unknownNCT02423837Phase 3